Abstract 1179P
Background
Recent reports have been shown an increased risk of de-novo malignancies in liver transplant recipients (LTRs) which is reported to be a leading cause of mortality in these patients. The aim of this systematic review and meta-analysis was to assess the prevalence of skin cancer in LTRs.
Methods
We systematically searched in five databases till 20th April 2023 through the search term ("liver transplantation" OR "liver transplant") AND ("skin cancer" OR "melanoma" OR "squamous cell carcinoma" OR "non-melanoma skin cancer" OR "post-transplant cancer" OR "post transplant cancer"). We used random effect model to overcome the significant heterogeneity we observed.
Results
A total of 34 studies, with 147154 LTRs were included. The pooled prevalence of skin cancer (all types) was 4.8% (95%confidence interval (CI): 3.6-6.5). Subgroup analysis based upon the follow up duration of each study, indicated that skin cancer prevalence increased with long duration of follow up: 0-4 years, 2.4% (95%CI: 0.5-9.9), 4-8 years, 4.2% (95%CI 2.9-6.2), and >8 years, 7.6% (95%CI: 4.7-12). Australia followed by South America had the highest prevalence of skin cancer, 20.6% (95%CI: 12.9-31.3), and 9.4% (95%CI: 5.8-14.8), in order; while Asia had the lowest prevalence 0.4% (95%CI: 0-3.8). The most common type of skin cancers was non-melanoma skin cancer reported as a combined type with a prevalence of 2.9% (95%CI: 1.1-6.9), followed by squamous cell carcinoma, basal cell carcinoma and Bowen’s cancer, 2.5% (95%CI: 1.4-4.4), 2.5% (95%CI: 1.5-4.1) and 0.8% (95%CI: 0.2-3.2), in order.
Conclusions
Consistent with what it has been reported for other organ transplants, the results from this study showed that skin cancer following liver transplantation is not rare. LTRs in Australia should receive annual dermatologic examination due to their high prevalence of skin cancers. Moreover, non-melanoma skin cancers may be the prevalent type if skin cancer is suspected in LTRs. Substantial dermatological surveillance programs are recommended in LTRs to improve quality of life as well as the associated mortality; especially with the increased prevalence after long follow up durations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1129P - Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
Presenter: Marlana Orloff
Session: Poster session 13
1130P - Tebentafusp (tebe) in an ongoing cohort of 72 French patients (pts) with metastatic uveal melanoma (mUM)
Presenter: Leah Mailly-Giacchetti
Session: Poster session 13
1131P - Management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting
Presenter: Mauricio Fernando Ribeiro
Session: Poster session 13
1132P - Chemokine expression in uveal melanoma and association with tumor genetics and response to immunotherapy
Presenter: Aparna Nallagangula
Session: Poster session 13
1133P - SF3B1 mutation predicts improved overall survival in metastatic uveal melanoma patients: Molecular and clinical correlates
Presenter: Luis del Carpio Huerta
Session: Poster session 13
1134P - Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM)
Presenter: Isabella Glitza
Session: Poster session 13
1135P - Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204
Presenter: Raymond Huang
Session: Poster session 13
1136P - Regorafenib combined with BRAF-/MEK-inhibitors for the treatment of refractory melanoma brain metastases
Presenter: Iris Dirven
Session: Poster session 13
1138P - Intralesional administration of L19IL2/L19TNF in difficult-to-treat non-melanoma skin cancer shows a favorable safety profile and preliminary clinical activity
Presenter: Lukas Flatz
Session: Poster session 13